Published in Infect Immun on February 01, 1984
Cholera. Clin Microbiol Rev (1995) 12.33
Toxin, toxin-coregulated pili, and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans. J Exp Med (1988) 9.19
Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques. Infect Immun (1988) 4.44
Coli surface antigens 1 and 3 of colonization factor antigen II-positive enterotoxigenic Escherichia coli: morphology, purification, and immune responses in humans. Infect Immun (1984) 3.63
Interventions for the control of diarrhoeal diseases among young children: rotavirus and cholera immunization. Bull World Health Organ (1985) 3.59
Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans. J Clin Invest (1987) 3.03
Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol (2012) 2.65
Experimental non-O group 1 Vibrio cholerae gastroenteritis in humans. J Clin Invest (1990) 2.33
Specific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalent Salmonella typhi-Shigella sonnei vaccine or infection by pathogenic S. sonnei. Infect Immun (1990) 1.64
Safety, immunogenicity, and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi Ty21a. Infect Immun (1990) 1.55
Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin. Infect Immun (1992) 1.45
Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults. Infect Immun (1989) 1.41
Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen. Infect Immun (1992) 1.39
Immunogenicity of Vibrio cholerae O1 toxin-coregulated pili in experimental and clinical cholera. Infect Immun (1991) 1.39
Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial. Infect Immun (1992) 1.35
Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG. Infect Immun (1996) 1.32
Comparison of the Vibrio cholerae hemagglutinin/protease and the Pseudomonas aeruginosa elastase. Infect Immun (1990) 1.31
Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults. Infect Immun (2002) 1.15
Cell-associated hemagglutinin-deficient mutant of Vibrio cholerae. Infect Immun (1987) 1.12
Vibrio cholerae: lessons for mucosal vaccine design. Expert Rev Vaccines (2011) 1.00
Molecular cloning and nucleotide sequence analysis of cholera toxin genes of the CtxA- Vibrio cholerae strain Texas Star-SR. Infect Immun (1990) 0.93
Immunogenicity of two formulations of oral cholera vaccine comprised of killed whole vibrios and the B subunit of cholera toxin. Infect Immun (1989) 0.93
Compared colonizing and immunizing efficiency of toxinogenic (A+ B+) Vibrio cholerae and an A- B+ mutant (Texas Star-SR) studied in adult rabbits. Infect Immun (1984) 0.87
Human immune response to Vibrio cholerae O1 whole cells and isolated outer membrane antigens. Infect Immun (1989) 0.87
The utility of human challenge studies in vaccine development: lessons learned from cholera. Vaccine (Auckl) (2011) 0.82
Exploiting cholera vaccines as a versatile antigen delivery platform. Biotechnol Lett (2007) 0.79
Preparation of procoligenoids from Escherichia coli heat-labile enterotoxins. Infect Immun (1984) 0.78
Immunizing adult female mice with a TcpA-A2-CTB chimera provides a high level of protection for their pups in the infant mouse model of cholera. PLoS Negl Trop Dis (2014) 0.76
Oral delivery of Brucella spp. recombinant protein U-Omp16 abrogates the IgE-mediated milk allergy. Hum Vaccin Immunother (2014) 0.76
Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry (1965) 96.68
Observations on the pathogenic properties of the K88, Hly and Ent plasmids of Escherichia coli with particular reference to porcine diarrhoea. J Med Microbiol (1971) 11.97
Production of Shigella dysenteriae type 1-like cytotoxin by Escherichia coli. J Infect Dis (1982) 8.05
Endemic cholera in rural Bangladesh, 1966-1980. Am J Epidemiol (1982) 4.93
Vibrio cholerae adherence and colonization in experimental cholera: electron microscopic studies. Infect Immun (1976) 4.03
Duration of infection-derived immunity to cholera. J Infect Dis (1981) 3.60
Pathogenesis of experimental cholera: identification of choleragen (procholeragen A) by disc immunoelectrophoresis and its differentiation from cholera mucinase. J Immunol (1966) 3.31
Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae. J Infect Dis (1982) 3.28
Selection and characteristics of a Vibrio cholerae mutant lacking the A (ADP-ribosylating) portion of the cholera enterotoxin. Proc Natl Acad Sci U S A (1979) 3.17
Studies on toxinogenesis in Vibrio cholerae. III. Characterization of nontoxinogenic mutants in vitro and in experimental animals. J Clin Invest (1975) 3.12
Isolation of enterotoxin structural gene deletion mutations in Vibrio cholerae induced by two mutagenic vibriophages. Proc Natl Acad Sci U S A (1982) 2.92
Response of man to infection with Vibrio cholerae. II. Protection from illness afforded by previous disease and vaccine. J Infect Dis (1974) 2.73
Serological studies in cholera. 3. Serum toxin neutralization--rise in titre in response to infection with Vibrio cholerae, and the level in the "normal" population of East Pakistan. Bull World Health Organ (1968) 2.71
Longitudinal studies of infectious diseases and physical growth of children in rural Bangladesh. II. Incidence of diarrhea and association with known pathogens. Am J Epidemiol (1982) 2.65
Identification and preliminary characterization of Vibrio cholerae outer membrane proteins. J Bacteriol (1981) 2.58
Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity. Trans R Soc Trop Med Hyg (1979) 2.51
Intestinal antibody responses after immunisation with cholera B subunit. Lancet (1982) 2.13
The pathogenicity of nonenterotoxigenic Vibrio cholerae serogroup O1 biotype El Tor isolated from sewage water in Brazil. J Infect Dis (1982) 2.13
Oral immunization of dogs with purified cholera toxin, crude cholera toxin, or B subunit: evidence for synergistic protection by antitoxic and antibacterial mechanisms. Infect Immun (1982) 1.87
Vibrio factors cause rapid fluid accumulation in suckling mice. Infect Immun (1983) 1.78
Enterotoxigenicity of enteropathogenic serotypes of Escherichia coli isolated from infants with epidemic diarrhea. Infect Immun (1978) 1.74
Medium-dependent production of extracellular enterotoxins by non-O-1 Vibrio cholerae, Vibrio mimicus, and Vibrio fluvialis. Appl Environ Microbiol (1983) 1.73
Selective vs. nonselective media and direct plating vs. enrichment technique in isolation of Vibrio cholerae: recommendations for clinical laboratories. J Infect Dis (1980) 1.61
Microtiter enzyme-linked immunosorbent assay for immunoglobulin G cholera antitoxin in humans: method and correlation with rabbit skin vascular permeability factor technique. Infect Immun (1980) 1.46
Cloned cholera enterotoxin genes in study and prevention of cholera. Lancet (1981) 1.32
Field trials of monovalent Ogawa and Inaba cholera vaccines in rural Bangladesh--three years of observation. Bull World Health Organ (1973) 1.31
Protection in rabbits induced by the Texas Star-SR attenuated A-B+ mutant candidate live oral cholera vaccine. Infect Immun (1982) 1.23
Antigenicity of purified glutaraldehyde-treated cholera toxoid administered orally. Infect Immun (1978) 1.22
Procholeragenoid: a safe and effective antigen for oral immunization against experimental cholera. Infect Immun (1983) 1.19
Live oral cholera vaccine: evaluation of the clinical effectiveness of two strains in humans. Infect Immun (1974) 1.18
A new cholera toxin. Lancet (1983) 1.14
The problem of emesis during oral glucose-electrolytes therapy given from the onset of severe cholera. Trans R Soc Trop Med Hyg (1979) 1.06
Immunology of cholera. Curr Top Microbiol Immunol (1975) 1.05
Travellers' diarrhoea: prospects for successful immunoprophylaxis. Scand J Gastroenterol Suppl (1983) 1.04
Texas Star-SR: attenuated "Vibrio cholerae" oral vaccine candidate. Dev Biol Stand (1983) 1.03
Duodenal isolation of Salmonella typhi by string capsule in acute typhoid fever. J Clin Microbiol (1976) 0.99
Microtiter enzyme-linked immunosorbent assay for immunoglobulin g cholera antitoxin in humans: sensitivity and specificity. Infect Immun (1980) 0.93
Current status of an oral B subunit whole cell cholera vaccine. Dev Biol Stand (1983) 0.83
Not one but four possible oral vaccines for cholera under study. JAMA (1982) 0.81
Complete genome sequence of enterohemorrhagic Escherichia coli O157:H7 and genomic comparison with a laboratory strain K-12. DNA Res (2001) 15.22
Attaching and effacing activities of rabbit and human enteropathogenic Escherichia coli in pig and rabbit intestines. Infect Immun (1983) 12.81
Transient left ventricular apical ballooning without coronary artery stenosis: a novel heart syndrome mimicking acute myocardial infarction. Angina Pectoris-Myocardial Infarction Investigations in Japan. J Am Coll Cardiol (2001) 12.56
Cholera. Clin Microbiol Rev (1995) 12.33
Escherichia coli that cause diarrhea: enterotoxigenic, enteropathogenic, enteroinvasive, enterohemorrhagic, and enteroadherent. J Infect Dis (1987) 12.26
Escherichia coli strains that cause diarrhoea but do not produce heat-labile or heat-stable enterotoxins and are non-invasive. Lancet (1978) 10.29
Pathogenesis of experimental cholera: biologic ativities of purified procholeragen A. J Immunol (1966) 9.39
Toxin, toxin-coregulated pili, and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans. J Exp Med (1988) 9.19
The diarrheal response of humans to some classic serotypes of enteropathogenic Escherichia coli is dependent on a plasmid encoding an enteroadhesiveness factor. J Infect Dis (1985) 9.18
Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ (1999) 8.93
Pathogenesis of experimental cholera. Preparation and isolation of choleragen and choleragenoid. J Exp Med (1969) 8.91
A DNA probe to identify enterohemorrhagic Escherichia coli of O157:H7 and other serotypes that cause hemorrhagic colitis and hemolytic uremic syndrome. J Infect Dis (1987) 8.19
Detection of an adherence factor of enteropathogenic Escherichia coli with a DNA probe. J Infect Dis (1985) 7.78
Isolation and characterization of homogeneous heat-labile enterotoxins with high specific activity from Escherichia coli cultures. Infect Immun (1979) 7.21
New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol Rev (1983) 7.16
Patterns of adherence of diarrheagenic Escherichia coli to HEp-2 cells. Pediatr Infect Dis J (1987) 7.15
Experimental Campylobacter jejuni infection in humans. J Infect Dis (1988) 7.05
A critical appraisal of 98.6 degrees F, the upper limit of the normal body temperature, and other legacies of Carl Reinhold August Wunderlich. JAMA (1992) 6.88
Plasmid-mediated adhesion in enteropathogenic Escherichia coli. J Pediatr Gastroenterol Nutr (1983) 6.59
Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet (1998) 6.09
Enteropathogenic Escherichia coli of classic serotypes associated with infant diarrhea: epidemiology and pathogenesis. Epidemiol Rev (1984) 5.98
Plasmid-mediated factors conferring diffuse and localized adherence of enteropathogenic Escherichia coli. Infect Immun (1985) 5.42
Epidemic Yersinia enterocolitica infection due to contaminated chocolate milk. N Engl J Med (1978) 5.39
Characterization of enteroadherent-aggregative Escherichia coli, a putative agent of diarrheal disease. J Infect Dis (1988) 5.30
Cholera and other vibrioses in the United States. N Engl J Med (1985) 5.17
Endemic cholera in rural Bangladesh, 1966-1980. Am J Epidemiol (1982) 4.93
Relative efficacy of blood, urine, rectal swab, bone-marrow, and rose-spot cultures for recovery of Salmonella typhi in typhoid fever. Lancet (1975) 4.85
Ethics and international research. BMJ (1997) 4.70
Prevention of diarrhea and pneumonia by zinc supplementation in children in developing countries: pooled analysis of randomized controlled trials. Zinc Investigators' Collaborative Group. J Pediatr (1999) 4.57
Role of the eaeA gene in experimental enteropathogenic Escherichia coli infection. J Clin Invest (1993) 4.53
Enteroaggregative Escherichia coli associated with persistent diarrhea in a cohort of rural children in India. J Infect Dis (1989) 4.52
Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques. Infect Immun (1988) 4.44
A sensitive and specific DNA probe to identify enteroaggregative Escherichia coli, a recently discovered diarrheal pathogen. J Infect Dis (1990) 4.43
Summary of an international workshop on typhoid fever. Rev Infect Dis (1986) 4.21
Detection and differentiation of iron-responsive avirulent mutants on Congo red agar. Infect Immun (1977) 4.09
Exclusive breastfeeding reduces acute respiratory infection and diarrhea deaths among infants in Dhaka slums. Pediatrics (2001) 4.05
Vibrio cholerae adherence and colonization in experimental cholera: electron microscopic studies. Infect Immun (1976) 4.03
Studies on toxinogenesis in Vibrio cholerae. I. Isolation of mutants with altered toxinogenicity. J Infect Dis (1974) 4.02
Role of a 60-megadalton plasmid and Shiga-like toxins in the pathogenesis of infection caused by enterohemorrhagic Escherichia coli O157:H7 in gnotobiotic piglets. Infect Immun (1987) 3.96
A two-year study of bacterial, viral, and parasitic agents associated with diarrhea in rural Bangladesh. J Infect Dis (1980) 3.96
Immunological cross-reactivity between a heat-labile enterotoxin(s) of Escherichia coli and subunits of Vibrio cholerae enterotoxin. Infect Immun (1978) 3.95
The critical role of iron in host-bacterial interactions. J Clin Invest (1978) 3.87
Demonstration of shared and unique immunological determinants in enterotoxins from Vibrio cholerae and Escherichia coli. Infect Immun (1978) 3.80
Therapeutic effects of oral zinc in acute and persistent diarrhea in children in developing countries: pooled analysis of randomized controlled trials. Am J Clin Nutr (2000) 3.77
A plasmid of enterohemorrhagic Escherichia coli O157:H7 is required for expression of a new fimbrial antigen and for adhesion to epithelial cells. Infect Immun (1987) 3.76
Handwashing to prevent diarrhea in day-care centers. Am J Epidemiol (1981) 3.75
Characterization and distribution of the hemagglutinins produced by Vibrio cholerae. Infect Immun (1982) 3.71
Inoculum size in shigellosis and implications for expected mode of transmission. J Infect Dis (1989) 3.71
Coli surface antigens 1 and 3 of colonization factor antigen II-positive enterotoxigenic Escherichia coli: morphology, purification, and immune responses in humans. Infect Immun (1984) 3.63
Duration of infection-derived immunity to cholera. J Infect Dis (1981) 3.60
Purification and characterization of the soluble hemagglutinin (cholera lectin)( produced by Vibrio cholerae. Infect Immun (1982) 3.50
Pathogenesis and immunology of experimental gonococcal infection: virulence of colony types of Neisseria gonorrhoeae for chicken embryos. Infect Immun (1973) 3.49
Immunological nonidentity of heat-labile enterotoxins from human and porcine enterotoxigenic Escherichia coli. Infect Immun (1981) 3.46
Pathogenesis of Shigella dysenteriae 1 (Shiga) dysentery. J Infect Dis (1973) 3.45
Validation of postmortem interviews to ascertain selected causes of death in children. Int J Epidemiol (1990) 3.42
Meta-analysis of intervention trials on case-management of pneumonia in community settings. Lancet (1992) 3.38
Modified Elek test for detection of heat-labile enterotoxin of enterotoxigenic Escherichia coli. J Clin Microbiol (1981) 3.37
Properties of homogeneous heat-labile enterotoxin from Escherichia coli. Infect Immun (1980) 3.36
Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol (1986) 3.33
Pathogenesis of experimental cholera: identification of choleragen (procholeragen A) by disc immunoelectrophoresis and its differentiation from cholera mucinase. J Immunol (1966) 3.31
Enteropathogenicity of Escherichia coli. I. Evaluation of mouse intestinal loops. Infect Immun (1971) 3.30
Aggregative adherence fimbriae I of enteroaggregative Escherichia coli mediate adherence to HEp-2 cells and hemagglutination of human erythrocytes. Infect Immun (1992) 3.30
Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae. J Infect Dis (1982) 3.28
Selection and characteristics of a Vibrio cholerae mutant lacking the A (ADP-ribosylating) portion of the cholera enterotoxin. Proc Natl Acad Sci U S A (1979) 3.17
Subunit number and arrangement in Escherichia coli heat-labile enterotoxin. Infect Immun (1981) 3.15
Heterogeneity of enteroaggregative Escherichia coli virulence demonstrated in volunteers. J Infect Dis (1995) 3.14
Studies on toxinogenesis in Vibrio cholerae. III. Characterization of nontoxinogenic mutants in vitro and in experimental animals. J Clin Invest (1975) 3.12
Effect of El Niño and ambient temperature on hospital admissions for diarrhoeal diseases in Peruvian children. Lancet (2000) 3.11
Identification of lethal toxin with the thermostable direct hemolysin produced by Vibrio parahaemolyticus, and some physicochemical properties of the purified toxin. Infect Immun (1976) 3.11
Chemical and physical properties of cholera exo-enterotoxin (choleragen) and its spontaneously formed toxoid (choleragenoid). Biochim Biophys Acta (1972) 3.11
Localization of cholera toxin in vivo. J Infect Dis (1972) 3.09
Recombinant nontoxinogenic Vibrio cholerae strains as attenuated cholera vaccine candidates. Nature (1984) 3.08
Diagnostic value of the Widal test in areas endemic for typhoid fever. Am J Trop Med Hyg (1978) 3.06
Giardiasis in day-care centers: evidence of person-to-person transmission. Pediatrics (1977) 3.06
Environmental and human isolates of Vibrio cholerae and Vibrio parahaemolyticus produce a Shigella dysenteriae 1 (Shiga)-like cytotoxin. Lancet (1984) 3.05
Production of highly purified choleragen and choleragenoid. J Infect Dis (1970) 3.05
Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans. J Clin Invest (1987) 3.03
Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci U S A (1997) 3.02
Purification and characterization of a hemolysin produced by Vibrio cholerae biotype El Tor: another toxic substance produced by cholera vibrios. Infect Immun (1979) 2.99
Procholeragenoid: an aggregated intermediate in the formation of choleragenoid. J Immunol (1971) 2.98
Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens. Lancet (1998) 2.98
Rates, timing and causes of neonatal deaths in rural India: implications for neonatal health programmes. Bull World Health Organ (2006) 2.90